peptide wiki

Mechanism

Acetylated and C-terminally amidated derivative of Semax, itself a synthetic analog of the ACTH(4-7) fragment (Met-Glu-His-Phe) extended with a Pro-Gly-Pro tail. The N-terminal acetyl and C-terminal amide groups are intended to slow enzymatic degradation and improve metabolic stability versus unmodified Semax. Proposed mechanisms include modulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, plus effects on the dopaminergic and serotonergic systems. It is not FDA-approved; Semax is registered as a nootropic/neuroprotective drug only in Russia and Ukraine, and the acetyl-amidate variant is a grey-market research compound with no controlled human efficacy data.

Studied uses

• cognitive enhancement and focus (research only)
• neuroprotection (animal and limited Russian clinical data on parent Semax)
• stress and attention modulation (research only)

Identification

CAS number	2920938-90-3
Molecular formula	C39H54N10O10S
Sequence	Ac-MEHFPGP-NH2
Typical dose	Vendor-reported intranasal use commonly 300-600 mcg/day; no validated human dosing for the acetyl-amidate variant
Half-life	Not well characterized for the amidated variant; modifications are intended to extend the very short (minutes-scale) half-life of unmodified Semax

Safety

Not FDA-approved for human use; sold as a research chemical only. Human safety data specific to the acetyl-amidate derivative are lacking. Not currently a WADA-named substance, but its regulatory and purity status is unverified outside of registered Semax products.